对钠-葡萄糖协同转运蛋白2抑制剂与心力衰竭的评论 - Suppr

Suppr

超能文献

Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure.

作者信息

Cure Erkan, Cumhur Cure Medine

机构信息

Internal Medicine, Jinemed Health Group, Istanbul,Turkey.

Biochemistry, Private Practice, Istanbul, Turkey.

出版信息

Am J Cardiol. 2020 May 15;125(10):1602. doi: 10.1016/j.amjcard.2020.03.001. Epub 2020 Mar 5.

DOI:10.1016/j.amjcard.2020.03.001

PMID:32241553

Abstract

摘要

相似文献

Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure.

Am J Cardiol. 2020 May 15;125(10):1602. doi: 10.1016/j.amjcard.2020.03.001. Epub 2020 Mar 5.

Treatment of Hypertension to Prevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 Inhibitors.

JACC Heart Fail. 2018 Jan;6(1):85. doi: 10.1016/j.jchf.2017.07.008.

SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure.

Eur J Heart Fail. 2021 Jan;23(1):27-30. doi: 10.1002/ejhf.2075. Epub 2020 Dec 29.

Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.

Heart Fail Rev. 2021 Jul;26(4):953-960. doi: 10.1007/s10741-020-09925-z.

Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.

Arq Bras Cardiol. 2021 Feb;116(2):355-358. doi: 10.36660/abc.20210031.

Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.

Eur Heart J. 2020 Sep 21;41(36):3379-3383. doi: 10.1093/eurheartj/ehaa810.

Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?

Diabetes Obes Metab. 2021 Sep;23(9):2194-2196. doi: 10.1111/dom.14444. Epub 2021 Jun 9.

Beyond the myocardium: Sodium-glucose co-transporter-2 inhibitors in heart failure.

Diabetes Obes Metab. 2021 May;23(5):1215-1218. doi: 10.1111/dom.14320. Epub 2021 Feb 26.

Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.

Eur Heart J. 2021 Dec 21;42(48):4887-4890. doi: 10.1093/eurheartj/ehab704.

Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline Anemia.

Am J Cardiol. 2022 Sep 15;179:111-114. doi: 10.1016/j.amjcard.2022.06.011. Epub 2022 Jul 22.

引用本文的文献

Alpha-lipoic acid may protect patients with diabetes against COVID-19 infection.

Med Hypotheses. 2020 Oct;143:110185. doi: 10.1016/j.mehy.2020.110185. Epub 2020 Aug 14.

Comment on "Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?".

Diabetes Res Clin Pract. 2020 Jun;164:108184. doi: 10.1016/j.diabres.2020.108184. Epub 2020 Apr 30.

Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis.

Diabetes Metab Syndr. 2020 Jul-Aug;14(4):405-406. doi: 10.1016/j.dsx.2020.04.024. Epub 2020 Apr 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure.

作者信息

Cure Erkan, Cumhur Cure Medine

机构信息

Internal Medicine, Jinemed Health Group, Istanbul,Turkey.

Biochemistry, Private Practice, Istanbul, Turkey.

出版信息

Am J Cardiol. 2020 May 15;125(10):1602. doi: 10.1016/j.amjcard.2020.03.001. Epub 2020 Mar 5.

DOI:10.1016/j.amjcard.2020.03.001

PMID:32241553

Abstract

摘要

相似文献

Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure.

Am J Cardiol. 2020 May 15;125(10):1602. doi: 10.1016/j.amjcard.2020.03.001. Epub 2020 Mar 5.

Treatment of Hypertension to Prevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 Inhibitors.

JACC Heart Fail. 2018 Jan;6(1):85. doi: 10.1016/j.jchf.2017.07.008.

SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure.

Eur J Heart Fail. 2021 Jan;23(1):27-30. doi: 10.1002/ejhf.2075. Epub 2020 Dec 29.

Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.

Heart Fail Rev. 2021 Jul;26(4):953-960. doi: 10.1007/s10741-020-09925-z.

Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.

Arq Bras Cardiol. 2021 Feb;116(2):355-358. doi: 10.36660/abc.20210031.

Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.

Eur Heart J. 2020 Sep 21;41(36):3379-3383. doi: 10.1093/eurheartj/ehaa810.

Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?

Diabetes Obes Metab. 2021 Sep;23(9):2194-2196. doi: 10.1111/dom.14444. Epub 2021 Jun 9.

Beyond the myocardium: Sodium-glucose co-transporter-2 inhibitors in heart failure.

Diabetes Obes Metab. 2021 May;23(5):1215-1218. doi: 10.1111/dom.14320. Epub 2021 Feb 26.

Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.

Eur Heart J. 2021 Dec 21;42(48):4887-4890. doi: 10.1093/eurheartj/ehab704.

Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline Anemia.

Am J Cardiol. 2022 Sep 15;179:111-114. doi: 10.1016/j.amjcard.2022.06.011. Epub 2022 Jul 22.

引用本文的文献

Alpha-lipoic acid may protect patients with diabetes against COVID-19 infection.

Med Hypotheses. 2020 Oct;143:110185. doi: 10.1016/j.mehy.2020.110185. Epub 2020 Aug 14.

Comment on "Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?".

Diabetes Res Clin Pract. 2020 Jun;164:108184. doi: 10.1016/j.diabres.2020.108184. Epub 2020 Apr 30.

Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis.

Diabetes Metab Syndr. 2020 Jul-Aug;14(4):405-406. doi: 10.1016/j.dsx.2020.04.024. Epub 2020 Apr 21.